Press Releases :: NeoGenomics, Inc. (NEO)

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Menu

Test Search

Year

Category

Jul 28, 2026 4:05 pm EDT

NeoGenomics Reports Second Quarter 2026 Results

Jul 20, 2026 5:23 pm EDT

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

Jul 9, 2026 7:05 am EDT

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Jul 7, 2026 7:05 am EDT

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

Jun 25, 2026 7:05 am EDT

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

Jun 17, 2026 6:00 am EDT

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

Jun 15, 2026 5:24 pm EDT

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

May 26, 2026 7:05 am EDT

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

May 15, 2026 9:05 am EDT

NeoGenomics to Participate in Upcoming Investor Conferences

Apr 28, 2026 4:05 pm EDT

NeoGenomics Reports First Quarter 2026 Results